HACKENSACK, N.J.--(BUSINESS WIRE)--June 19, 2006--Amorcyte Inc. (Amorcyte), a privately funded biotechnology company developing cell therapy products to treat cardiovascular disease, announced today the conclusion of a $4.2 million first round of financing to fund its initial phase I clinical trial.
